entity

Are

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Are: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections
22Hypotheses
2Analyses
1Outgoing
2Incoming
20Experiments
2Debates

No AI portrait yet

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Claude Code (Anthropic Agent SDK)

ai_tool · 0 words

Ventral Tegmental Area Dopamine Neurons in Parkinson's Disease

cell · 2730 words

Lateral Preoptic Area (LPOA) Neurons

cell · 2493 words

Hypothalamic Preoptic Area Sleep-Active Neurons

cell · 2013 words

GABAergic Preoptic Area Neurons

cell · 1994 words

Ventral Tegmental Area Glutamatergic Neurons

cell · 1745 words

Outgoing (1)

TargetRelationTypeStr
Inflammatory Mediatorsregulatesprocess0.80

Incoming (2)

SourceRelationTypeStr
NFE2L2component_ofgene0.90
NRF2activatesprotein0.90

Targeting Hypotheses (22)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Senescent Microglia Resolution via Maresins-Senolytics Combi 0.791 neurodegeneration Neuroinflammation resolution mechanisms
Synaptic Vesicle Cycle Hijacking: Shared Convergent Mechanis 0.760 neurodegeneration -
Near-infrared light therapy stimulates COX4-dependent mitoch 0.742 neurodegeneration Mitochondrial transfer between astrocyte
Endosomal trafficking defects are the common upstream lesion 0.730 neurodegeneration What determines the temporal sequence of
NRF2-Mediated Proteostatic Convergence: Shared Oxidative Str 0.700 neurodegeneration -
Microglial TREM2 state determines whether C1q-tagged substra 0.670 neurodegeneration Does C1q function differ based on subcel
Vascular mural cell degeneration precedes and exacerbates pa 0.661 alzheimers SEA-AD Single-Cell Analysis: Cell-Type V
Endosomal-Retromer Trafficking Defect as a Shared Sorting Fa 0.640 neurodegeneration Cross-disease neurodegeneration mechanis
early PD proteogenomic hubs that are both causal enough and 0.626 neurodegeneration Proteogenomic Network Hubs as Druggable
LYTL and JIP4-dependent lysosomal remodeling may show mutant 0.580 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
Circadian-Gated Maresin Biosynthesis Amplification 0.557 neurodegeneration Neuroinflammation resolution mechanisms
Disease-Elevated CHI3L1/CHIT1 Chitinases Are Biomarkers and 0.502 als What are the mechanisms by which microgl
Rare TREM2-TYROBP pathway variants complement standard PRS b 0.380 late-onset-alzheimers Polygenic Risk Score Analysis for Late-O
Convergent NF-κB enhancers across diverse priming stimuli sh 0.380 alzheimers Do different priming stimuli require dis
protective chromatin remodeling defines the therapeutic wind 0.345 neurodegeneration Are DNA methylation changes in neurodege
age-linked CpG drift is the actionable driver in: Are DNA me 0.344 neurodegeneration Are DNA methylation changes in neurodege
age-linked CpG drift is the actionable driver in: Are age-re 0.344 neurodegeneration Are age-related DNA methylation changes
ATAC-seq accessibility separates causal from compensatory st 0.342 neurodegeneration Are DNA methylation changes in neurodege
Poorly lipidated APOE4 particles are preferentially routed t 0.340 molecular-biology Does APOE4's reduced lipid-binding direc
ATAC-seq accessibility separates causal from compensatory st 0.327 neurodegeneration Are age-related DNA methylation changes
protective chromatin remodeling defines the therapeutic wind 0.326 neurodegeneration Are age-related DNA methylation changes
Stress-Activated Retrotransposon Epigenetic Regulation (SARE 0.000 - Do different priming stimuli require dis

Mentioning Analyses (2)

Scientific analyses that reference this entity

Neuroinflammation resolution mechanisms and pro-resolving mediators

neurodegeneration | 2026-04-01 | 14 hypotheses Top: 0.791

Autophagy-lysosome pathway convergence across neurodegenerative diseases

neurodegeneration | 2026-04-01 | 12 hypotheses Top: 0.777

Experiments (20)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Longitudinal dietary change analysis and ADRD risk over 10 years clinical Alzheimer's disease and relate 0.930 0.00 human patients proposed N/A
Irisin effects on angiogenesis in human endothelial cells exploratory bone fracture 0.900 0.00 human umbilical vein endotheli proposed N/A
Proposed experiment from debate on Senolytics targeting p16/p21+ senes falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000
cGAS-STING Pathway Validation Study in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $7,100,000
Microglial Aging and Immune Memory in Neurodegeneration — Training the validation Alzheimer's Disease 0.400 0.50 human proposed $2,960,000
Microglial Contributions to Huntington's Disease Pathogenesis validation Neuroinflammation 0.400 0.50 human proposed $2,960,000
Mixed Pathology Effects on Parkinson's Disease Progression and Treatme clinical Alzheimer's Disease 0.400 0.50 human proposed $5,460,000
NLRP3 Inflammasome Validation Study in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease clinical Alzheimer's Disease 0.400 0.50 human proposed $5,460,000
Traumatic Brain Injury and Alzheimer's Disease Relationship validation Alzheimer's Disease 0.400 0.50 human proposed $3,000,000
s:** - Test MCU overexpression specifically in layer II neurons in hea falsification Neurodegeneration 0.400 0.50 mouse proposed $200,000
Proposed experiment from debate on Mitochondrial transfer between astr falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000
Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso validation Parkinson's Disease 0.400 0.50 human proposed $3,000,000
Ferroptosis Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
GLP-1 Agonist Neuroprotection Mechanism in PD clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Cytochrome Therapeutics clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Peroxisomal Dysfunction Validation in Parkinson's Disease validation Parkinson's Disease 0.400 0.50 human proposed $2,280,000
Prodromal Parkinson's Disease Biomarker Development — Early Detection clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease validation Parkinson's Disease 0.400 0.50 human proposed $2,730,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the S [PMID:37738560] Justice JN, Leng XI, LeBrasseur NK, Tchk J Gerontol A Biol Sci Med Sci 2024 1
Increased mitophagy protects cochlear hair cells from aminoglycoside-induced dam [PMID:35471096] Zhang Y, Fang Q, Wang H, Qi J, Sun S, Li Autophagy 2023 1
Sex differences in autophagy-mediated diseases: toward precision medicine. [PMID:32264724] Shang D, Wang L, Klionsky DJ, Cheng H, Z Autophagy 2021 1
Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populatio [PMID:33144684] He D, Wang D, Lu P, Yang N, Xue Z, Zhu X Oncogene 2021 1
BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains. [PMID:32722981] Wu X, Zheng Y, Liu M, Li Y, Ma S, Tang W Autophagy 2021 1
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells [PMID:26657143] Chang J, Wang Y, Shao L, Laberge RM, Dem Nat Med 2016 1
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. [PMID:25754370] Zhu Y, Tchkonia T, Pirtskhalava T, Gower Aging Cell 2015 1
SIRT5 regulation of ammonia-induced autophagy and mitophagy. [PMID:25700560] Polletta L, Vernucci E, Carnevale I, Arc Autophagy 2015 1
PRKAB2 as a tumor suppressor in renal cell carcinoma: inhibiting mitophagy via t [PMID:41612594] Chen K, Zhang Y, Ruan H, Wei Z, Wang K, Autophagy 2026 0
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990] Keller A Annual review of physiology 2026 0
ROS-responsive nanogels for brain targeted delivery of icariin in the treatment [PMID:41197818] ["Li X", "Huang J", "Zhou Y", "Chen X", International journal of pharm 2026 0
Single-Cell RNA Sequencing and Network Pharmacology Reveal the Potential Role of [PMID:41610872] ["Niu J", "Wang L", "Qi J", "Lu G"] The journal of gene medicine 2026 0
Integrated Profiling of DEHP-Induced Hippocampal Neurotoxicity in Adult Female R [PMID:41600627] Bai J, Li J, Tang L, Sun W, Gao F, Zhang Toxics 2026 0
Senolytic elimination of therapy-induced senescent cells by ABT-263 improves che [PMID:41423036] Zhang D, Zhu J, Zou R, Zhang H, Yu BP, L Biochemical pharmacology 2026 0
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811] Wang Y, Zhang Z, Cao L, Huang S, Huang X J Ethnopharmacol 2026 0
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710] Yang X, Xiao JH, Li X, Liu RM, Yuan Q J Ethnopharmacol 2026 0
Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296] Maier AD, Laurentiussen CO, Michaelsen S Acta Neuropathol Commun 2026 0
Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797] Prabhudesai S, Thirugnanam K, Song X, Ya Life Sci Alliance 2026 0
Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860] Li J, Li A, Ye C, Zhang L, Jiang M et al Mol Neurodegener 2026 0
FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210] Sun F, Zhao Y, Do J, Cheng P, Li E et al Nat Commun 2026 0

Debates (2)

Multi-agent debates referencing this entity

Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal th

closed · Rounds: 4 · Score: 0.90 · 2026-04-06

SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re

closed · Rounds: 4 · Score: 0.83 · 2026-04-06

Related Research

Hypotheses and analyses mentioning Are in their description or question text

Microglial TREM2 state determines whether C1q-tagged substrates are cleared adap

Score: 0.670 · neurodegeneration · 2026-04-25

This hypothesis reconciles conflicting C1q phenotypes by placing receiver-cell state downstream of a common upstream C1q

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

Endosomal-Retromer Trafficking Defect as a Shared Sorting Failure

Score: 0.640 · neurodegeneration · 2026-04-28

Disrupted retrieval of cargo from endosomes to the trans-Golgi network (retromer dysfunction) impairs processing of APP,

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro

LYTL and JIP4-dependent lysosomal remodeling may show mutant-selective amplifica

Score: 0.580 · neurodegeneration · 2026-04-24

A more mechanistic but less translationally mature possibility is that G2019S does not strongly alter total phospho-Rab

Circadian-Gated Maresin Biosynthesis Amplification

Score: 0.557 · neurodegeneration · 2026-04-02

## Mechanistic Overview Circadian-Gated Maresin Biosynthesis Amplification starts from the claim that modulating ALOX12

Disease-Elevated CHI3L1/CHIT1 Chitinases Are Biomarkers and Partial Compensators

Score: 0.502 · als · 2026-04-26

CHI3L1 (YKL-40), CHIT1 (chitotriosidase), and CHI3L2 are among the most consistently elevated proteins in ALS biofluids

Rare TREM2-TYROBP pathway variants complement standard PRS by identifying microg

Score: 0.380 · late-onset-alzheimers · 2026-04-26

We hypothesize that rare loss-of-function variants in microglial-expressed genes within the TREM2-TYROBP signaling casca

Convergent NF-κB enhancers across diverse priming stimuli share therapeutic vuln

Score: 0.380 · alzheimers · 2026-04-26

Despite different initial triggers (LPS, β-amyloid, aging), primed microglia may converge on a common 'epigenetic primin

protective chromatin remodeling defines the therapeutic window for: Are DNA meth

Score: 0.345 · neurodegeneration · 2026-04-26

The same signal may be beneficial early and damaging late. Testing protective chromatin remodeling with single-cell meth

age-linked CpG drift is the actionable driver in: Are DNA methylation changes in

Score: 0.344 · neurodegeneration · 2026-04-26

The gap can be tested by treating age-linked CpG drift as an upstream driver rather than a passive correlate. If true, p

age-linked CpG drift is the actionable driver in: Are age-related DNA methylatio

Score: 0.344 · neurodegeneration · 2026-04-26

The gap can be tested by treating age-linked CpG drift as an upstream driver rather than a passive correlate. If true, p

ATAC-seq accessibility separates causal from compensatory states in: Are DNA met

Score: 0.342 · neurodegeneration · 2026-04-26

A longitudinal biomarker panel centered on ATAC-seq accessibility can distinguish harmful mechanisms from protective ada

Poorly lipidated APOE4 particles are preferentially routed through LDLR/LRP1 int

Score: 0.340 · molecular-biology · 2026-04-24

This is the weakest mechanistic proposal. It attempts to connect extracellular apoE particle quality to intracellular ER

ATAC-seq accessibility separates causal from compensatory states in: Are age-rel

Score: 0.327 · neurodegeneration · 2026-04-26

A longitudinal biomarker panel centered on ATAC-seq accessibility can distinguish harmful mechanisms from protective ada